APO Research
Talk to an analyst

APO RESEARCH · REPORT

SPECT and PET Radiopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global SPECT and PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchSPECT and PET Radiopharmaceuticals Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal SPECT and PET Radiopharmaceuticals Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal SPECT and PET Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SPECT and PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal SPECT and PET Radiopharmaceuticals Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global SPECT and PET Radiopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for SPECT and PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SPECT and PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SPECT and PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the SPECT and PET Radiopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the SPECT and PET Radiopharmaceuticals market include China Isotope & Radiation, Novartis, Eli Lilly, Dongcheng, Bayer, SIEMENS, Mundipharma, Lantheus and Jubilant Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global SPECT and PET Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SPECT and PET Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SPECT and PET Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the SPECT and PET Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

SPECT and PET Radiopharmaceuticals Segment by Company

China Isotope & Radiation

Novartis

Eli Lilly

Dongcheng

Bayer

SIEMENS

Mundipharma

Lantheus

Jubilant Pharma

GE Healthcare

Curium Pharma

Cardinal Health

Bracco Imaging

Aurobindo Pharma

SPECT and PET Radiopharmaceuticals Segment by Type

Diagnostic Radiopharmaceuticals

Therapeutic Radiopharmaceuticals

SPECT and PET Radiopharmaceuticals Segment by Application

Hospitals

Clinics

Others

SPECT and PET Radiopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global SPECT and PET Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions SPECT and PET Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify SPECT and PET Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze SPECT and PET Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SPECT and PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SPECT and PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SPECT and PET Radiopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the SPECT and PET Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SPECT and PET Radiopharmaceuticals industry.

Chapter 3: Detailed analysis of SPECT and PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of SPECT and PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of SPECT and PET Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. SPECT and PET Radiopharmaceuticals Industry Trends Table 2. SPECT and PET Radiopharmaceuticals Industry Drivers Table 3. SPECT and PET Radiopharmaceuticals Industry Opportunities and Challenges Table 4. SPECT and PET Radiopharmaceuticals Industry Restraints Table 5. Global SPECT and PET Radiopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global SPECT and PET Radiopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global SPECT and PET Radiopharmaceuticals Sales Volume by Company (k units) & (2021-2026) Table 8. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Company (2021-2026) Table 9. Global SPECT and PET Radiopharmaceuticals Average Price (USD/unit) of Company (2021-2026) Table 10. Global SPECT and PET Radiopharmaceuticals Company Ranking, (2024-2026) & (USD Million) Table 11. Global SPECT and PET Radiopharmaceuticals Key Company Manufacturing Base & Headquarters Table 12. Global SPECT and PET Radiopharmaceuticals Company, Product Type & Application Table 13. Global SPECT and PET Radiopharmaceuticals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global SPECT and PET Radiopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diagnostic Radiopharmaceuticals Table 18. Significant Companies of Therapeutic Radiopharmaceuticals Table 19. Global SPECT and PET Radiopharmaceuticals Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global SPECT and PET Radiopharmaceuticals Sales Volume by Type (2021-2026) & (k units) Table 21. Global SPECT and PET Radiopharmaceuticals Sales Volume by Type (2027-2032) & (k units) Table 22. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Type (2021-2026) Table 23. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Type (2027-2032) Table 24. Global SPECT and PET Radiopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global SPECT and PET Radiopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global SPECT and PET Radiopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Type (2021-2026) Table 28. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global SPECT and PET Radiopharmaceuticals Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global SPECT and PET Radiopharmaceuticals Sales Volume by Application (2021-2026) & (k units) Table 34. Global SPECT and PET Radiopharmaceuticals Sales Volume by Application (2027-2032) & (k units) Table 35. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Application (2021-2026) Table 36. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Application (2027-2032) Table 37. Global SPECT and PET Radiopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global SPECT and PET Radiopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global SPECT and PET Radiopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Application (2021-2026) Table 41. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Application (2027-2032) Table 42. Global SPECT and PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global SPECT and PET Radiopharmaceuticals Sales by Region (2021-2026) & (k units) Table 44. Global SPECT and PET Radiopharmaceuticals Sales Market Share by Region (2021-2026) Table 45. Global SPECT and PET Radiopharmaceuticals Sales by Region (2027-2032) & (k units) Table 46. Global SPECT and PET Radiopharmaceuticals Sales Market Share by Region (2027-2032) Table 47. Global SPECT and PET Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global SPECT and PET Radiopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Region (2021-2026) Table 50. Global SPECT and PET Radiopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Region (2027-2032) Table 52. Global SPECT and PET Radiopharmaceuticals Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global SPECT and PET Radiopharmaceuticals Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global SPECT and PET Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global SPECT and PET Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global SPECT and PET Radiopharmaceuticals Sales by Country (2021-2026) & (k units) Table 57. Global SPECT and PET Radiopharmaceuticals Sales Market Share by Country (2021-2026) Table 58. Global SPECT and PET Radiopharmaceuticals Sales by Country (2027-2032) & (k units) Table 59. Global SPECT and PET Radiopharmaceuticals Sales Market Share by Country (2027-2032) Table 60. Global SPECT and PET Radiopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global SPECT and PET Radiopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 62. Global SPECT and PET Radiopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global SPECT and PET Radiopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 64. China Isotope & Radiation Company Information Table 65. China Isotope & Radiation Business Overview Table 66. China Isotope & Radiation SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. China Isotope & Radiation SPECT and PET Radiopharmaceuticals Product Portfolio Table 68. China Isotope & Radiation Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Novartis SPECT and PET Radiopharmaceuticals Product Portfolio Table 73. Novartis Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Eli Lilly SPECT and PET Radiopharmaceuticals Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Dongcheng Company Information Table 80. Dongcheng Business Overview Table 81. Dongcheng SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Dongcheng SPECT and PET Radiopharmaceuticals Product Portfolio Table 83. Dongcheng Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Bayer SPECT and PET Radiopharmaceuticals Product Portfolio Table 88. Bayer Recent Development Table 89. SIEMENS Company Information Table 90. SIEMENS Business Overview Table 91. SIEMENS SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. SIEMENS SPECT and PET Radiopharmaceuticals Product Portfolio Table 93. SIEMENS Recent Development Table 94. Mundipharma Company Information Table 95. Mundipharma Business Overview Table 96. Mundipharma SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Mundipharma SPECT and PET Radiopharmaceuticals Product Portfolio Table 98. Mundipharma Recent Development Table 99. Lantheus Company Information Table 100. Lantheus Business Overview Table 101. Lantheus SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Lantheus SPECT and PET Radiopharmaceuticals Product Portfolio Table 103. Lantheus Recent Development Table 104. Jubilant Pharma Company Information Table 105. Jubilant Pharma Business Overview Table 106. Jubilant Pharma SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Jubilant Pharma SPECT and PET Radiopharmaceuticals Product Portfolio Table 108. Jubilant Pharma Recent Development Table 109. GE Healthcare Company Information Table 110. GE Healthcare Business Overview Table 111. GE Healthcare SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. GE Healthcare SPECT and PET Radiopharmaceuticals Product Portfolio Table 113. GE Healthcare Recent Development Table 114. Curium Pharma Company Information Table 115. Curium Pharma Business Overview Table 116. Curium Pharma SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Curium Pharma SPECT and PET Radiopharmaceuticals Product Portfolio Table 118. Curium Pharma Recent Development Table 119. Cardinal Health Company Information Table 120. Cardinal Health Business Overview Table 121. Cardinal Health SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Cardinal Health SPECT and PET Radiopharmaceuticals Product Portfolio Table 123. Cardinal Health Recent Development Table 124. Bracco Imaging Company Information Table 125. Bracco Imaging Business Overview Table 126. Bracco Imaging SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Bracco Imaging SPECT and PET Radiopharmaceuticals Product Portfolio Table 128. Bracco Imaging Recent Development Table 129. Aurobindo Pharma Company Information Table 130. Aurobindo Pharma Business Overview Table 131. Aurobindo Pharma SPECT and PET Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. Aurobindo Pharma SPECT and PET Radiopharmaceuticals Product Portfolio Table 133. Aurobindo Pharma Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. SPECT and PET Radiopharmaceuticals Distributors List Table 137. SPECT and PET Radiopharmaceuticals Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. SPECT and PET Radiopharmaceuticals Product Image Figure 2. Global SPECT and PET Radiopharmaceuticals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 4. Global SPECT and PET Radiopharmaceuticals Sales (2021-2032) & (k units) Figure 5. Global SPECT and PET Radiopharmaceuticals Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global SPECT and PET Radiopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diagnostic Radiopharmaceuticals Image Figure 10. Therapeutic Radiopharmaceuticals Image Figure 11. Global SPECT and PET Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global SPECT and PET Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Type (2021-2032) Figure 14. Global SPECT and PET Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global SPECT and PET Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global SPECT and PET Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global SPECT and PET Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Application (2021-2032) Figure 23. Global SPECT and PET Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global SPECT and PET Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Application (2021-2032) Figure 26. Global SPECT and PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global SPECT and PET Radiopharmaceuticals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global SPECT and PET Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global SPECT and PET Radiopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 31. North America SPECT and PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 33. Europe SPECT and PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific SPECT and PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 37. South America SPECT and PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa SPECT and PET Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa SPECT and PET Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. SPECT and PET Radiopharmaceuticals Value Chain Figure 125. Manufacturing Cost Structure Figure 126. SPECT and PET Radiopharmaceuticals Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • China Isotope & Radiation
  • Novartis
  • Eli Lilly
  • Dongcheng
  • Bayer
  • SIEMENS
  • Mundipharma
  • Lantheus
  • Jubilant Pharma
  • GE Healthcare
  • Curium Pharma
  • Cardinal Health
  • Bracco Imaging
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  4. 1.2.2 Global SPECT and PET Radiopharmaceuticals Sales Volume (2021-2032)
  5. 1.2.3 Global SPECT and PET Radiopharmaceuticals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 SPECT and PET Radiopharmaceuticals Market Dynamics
  1. 2.1 SPECT and PET Radiopharmaceuticals Industry Trends
  2. 2.2 SPECT and PET Radiopharmaceuticals Industry Drivers
  3. 2.3 SPECT and PET Radiopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 SPECT and PET Radiopharmaceuticals Industry Restraints
3 SPECT and PET Radiopharmaceuticals Market by Company
  1. 3.1 Global SPECT and PET Radiopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global SPECT and PET Radiopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global SPECT and PET Radiopharmaceuticals Sales Volume by Company (2021-2026)
  4. 3.4 Global SPECT and PET Radiopharmaceuticals Average Price by Company (2021-2026)
  5. 3.5 Global SPECT and PET Radiopharmaceuticals Company Ranking (2024-2026)
  6. 3.6 Global SPECT and PET Radiopharmaceuticals Company Manufacturing Base and Headquarters
  7. 3.7 Global SPECT and PET Radiopharmaceuticals Company Product Type and Application
  8. 3.8 Global SPECT and PET Radiopharmaceuticals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global SPECT and PET Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 SPECT and PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 SPECT and PET Radiopharmaceuticals Market by Type
  1. 4.1 SPECT and PET Radiopharmaceuticals Type Introduction
  2. 4.1.1 Diagnostic Radiopharmaceuticals
  3. 4.1.2 Therapeutic Radiopharmaceuticals
  4. 4.2 Global SPECT and PET Radiopharmaceuticals Sales Volume by Type
  5. 4.2.1 Global SPECT and PET Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global SPECT and PET Radiopharmaceuticals Sales Volume by Type (2021-2032)
  7. 4.2.3 Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Type (2021-2032)
  8. 4.3 Global SPECT and PET Radiopharmaceuticals Sales Value by Type
  9. 4.3.1 Global SPECT and PET Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global SPECT and PET Radiopharmaceuticals Sales Value by Type (2021-2032)
  11. 4.3.3 Global SPECT and PET Radiopharmaceuticals Sales Value Share by Type (2021-2032)
5 SPECT and PET Radiopharmaceuticals Market by Application
  1. 5.1 SPECT and PET Radiopharmaceuticals Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global SPECT and PET Radiopharmaceuticals Sales Volume by Application
  6. 5.2.1 Global SPECT and PET Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global SPECT and PET Radiopharmaceuticals Sales Volume by Application (2021-2032)
  8. 5.2.3 Global SPECT and PET Radiopharmaceuticals Sales Volume Share by Application (2021-2032)
  9. 5.3 Global SPECT and PET Radiopharmaceuticals Sales Value by Application
  10. 5.3.1 Global SPECT and PET Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global SPECT and PET Radiopharmaceuticals Sales Value by Application (2021-2032)
  12. 5.3.3 Global SPECT and PET Radiopharmaceuticals Sales Value Share by Application (2021-2032)
6 SPECT and PET Radiopharmaceuticals Regional Sales and Value Analysis
  1. 6.1 Global SPECT and PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SPECT and PET Radiopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global SPECT and PET Radiopharmaceuticals Sales by Region: 2021-2026
  4. 6.2.2 Global SPECT and PET Radiopharmaceuticals Sales by Region (2027-2032)
  5. 6.3 Global SPECT and PET Radiopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global SPECT and PET Radiopharmaceuticals Sales Value by Region (2021-2032)
  7. 6.4.1 Global SPECT and PET Radiopharmaceuticals Sales Value by Region: 2021-2026
  8. 6.4.2 Global SPECT and PET Radiopharmaceuticals Sales Value by Region (2027-2032)
  9. 6.5 Global SPECT and PET Radiopharmaceuticals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  12. 6.6.2 North America SPECT and PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  15. 6.7.2 Europe SPECT and PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific SPECT and PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  21. 6.9.2 South America SPECT and PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa SPECT and PET Radiopharmaceuticals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa SPECT and PET Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 SPECT and PET Radiopharmaceuticals Country-level Sales and Value Analysis
  1. 7.1 Global SPECT and PET Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global SPECT and PET Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global SPECT and PET Radiopharmaceuticals Sales by Country (2021-2032)
  4. 7.3.1 Global SPECT and PET Radiopharmaceuticals Sales by Country (2021-2026)
  5. 7.3.2 Global SPECT and PET Radiopharmaceuticals Sales by Country (2027-2032)
  6. 7.4 Global SPECT and PET Radiopharmaceuticals Sales Value by Country (2021-2032)
  7. 7.4.1 Global SPECT and PET Radiopharmaceuticals Sales Value by Country (2021-2026)
  8. 7.4.2 Global SPECT and PET Radiopharmaceuticals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt SPECT and PET Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt SPECT and PET Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt SPECT and PET Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Isotope & Radiation
  2. 8.1.1 China Isotope & Radiation Company Information
  3. 8.1.2 China Isotope & Radiation Business Overview
  4. 8.1.3 China Isotope & Radiation SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China Isotope & Radiation SPECT and PET Radiopharmaceuticals Product Portfolio
  6. 8.1.5 China Isotope & Radiation Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis SPECT and PET Radiopharmaceuticals Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly SPECT and PET Radiopharmaceuticals Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Dongcheng
  20. 8.4.1 Dongcheng Company Information
  21. 8.4.2 Dongcheng Business Overview
  22. 8.4.3 Dongcheng SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dongcheng SPECT and PET Radiopharmaceuticals Product Portfolio
  24. 8.4.5 Dongcheng Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer SPECT and PET Radiopharmaceuticals Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 SIEMENS
  32. 8.6.1 SIEMENS Company Information
  33. 8.6.2 SIEMENS Business Overview
  34. 8.6.3 SIEMENS SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SIEMENS SPECT and PET Radiopharmaceuticals Product Portfolio
  36. 8.6.5 SIEMENS Recent Developments
  37. 8.7 Mundipharma
  38. 8.7.1 Mundipharma Company Information
  39. 8.7.2 Mundipharma Business Overview
  40. 8.7.3 Mundipharma SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mundipharma SPECT and PET Radiopharmaceuticals Product Portfolio
  42. 8.7.5 Mundipharma Recent Developments
  43. 8.8 Lantheus
  44. 8.8.1 Lantheus Company Information
  45. 8.8.2 Lantheus Business Overview
  46. 8.8.3 Lantheus SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lantheus SPECT and PET Radiopharmaceuticals Product Portfolio
  48. 8.8.5 Lantheus Recent Developments
  49. 8.9 Jubilant Pharma
  50. 8.9.1 Jubilant Pharma Company Information
  51. 8.9.2 Jubilant Pharma Business Overview
  52. 8.9.3 Jubilant Pharma SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jubilant Pharma SPECT and PET Radiopharmaceuticals Product Portfolio
  54. 8.9.5 Jubilant Pharma Recent Developments
  55. 8.10 GE Healthcare
  56. 8.10.1 GE Healthcare Company Information
  57. 8.10.2 GE Healthcare Business Overview
  58. 8.10.3 GE Healthcare SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GE Healthcare SPECT and PET Radiopharmaceuticals Product Portfolio
  60. 8.10.5 GE Healthcare Recent Developments
  61. 8.11 Curium Pharma
  62. 8.11.1 Curium Pharma Company Information
  63. 8.11.2 Curium Pharma Business Overview
  64. 8.11.3 Curium Pharma SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Curium Pharma SPECT and PET Radiopharmaceuticals Product Portfolio
  66. 8.11.5 Curium Pharma Recent Developments
  67. 8.12 Cardinal Health
  68. 8.12.1 Cardinal Health Company Information
  69. 8.12.2 Cardinal Health Business Overview
  70. 8.12.3 Cardinal Health SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Cardinal Health SPECT and PET Radiopharmaceuticals Product Portfolio
  72. 8.12.5 Cardinal Health Recent Developments
  73. 8.13 Bracco Imaging
  74. 8.13.1 Bracco Imaging Company Information
  75. 8.13.2 Bracco Imaging Business Overview
  76. 8.13.3 Bracco Imaging SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bracco Imaging SPECT and PET Radiopharmaceuticals Product Portfolio
  78. 8.13.5 Bracco Imaging Recent Developments
  79. 8.14 Aurobindo Pharma
  80. 8.14.1 Aurobindo Pharma Company Information
  81. 8.14.2 Aurobindo Pharma Business Overview
  82. 8.14.3 Aurobindo Pharma SPECT and PET Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Aurobindo Pharma SPECT and PET Radiopharmaceuticals Product Portfolio
  84. 8.14.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 SPECT and PET Radiopharmaceuticals Value Chain Analysis
  2. 9.1.1 SPECT and PET Radiopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 SPECT and PET Radiopharmaceuticals Sales Mode & Process
  6. 9.2 SPECT and PET Radiopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 SPECT and PET Radiopharmaceuticals Distributors
  9. 9.2.3 SPECT and PET Radiopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst